Diagnosis of inherited von Willebrand disease: Comparison of two methodologies and analysis of the discrepancies

Haemophilia

Volumn 20, Issue 4, 2014, Pages 559-567

  Costa Pinto, J ^a   Perez Rodriguez A ^a   Gomez del Castillo M D C ^a   Loures E ^a   Rodriguez Trillo A ^a   Batlle, J ^a   Lopez Fernandez M F ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Diagnosis management; Gene mutations; Multimeric analysis; Ristocetin cofactor; Von Willebrand disease; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; GENETIC ANALYSIS; GENETIC ANALYZER; HEMOSTASIS TESTING SYSTEM; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THROMBOCYTE FUNCTION ANALYZER; VON WILLEBRAND DISEASE; BLOOD; BLOOD ANALYSIS; CHEMISTRY; COMPARATIVE STUDY; GENETICS; METABOLISM; PROCEDURES; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; VON WILLEBRAND DISEASES;

BLOOD CHEMICAL ANALYSIS; HUMANS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84904717688     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12380     Document Type: Article

References (39)

1. Sadler JE, Budde U, Eikenboom J, Favaloro EJ, Hill FGH, Holmberg L, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on the von Willebrand Factor. J Thromb Haemost 2006; 4: 2013-4.
2. Favaloro EJ. von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost 2011;37: 440-55.
3. Federici AB. Classification of inherited von Willebrand disease and implications in clinical practice. Thromb Res 2009; 124(Supl.1): S2-6.
4. Nichols WL, Rick ME, Ortel TL, Montgomery RR, Sadler JE, Yawn BP, et al. Clinical and laboratory diagnosis of von Willebrand disease: A synopsis of 2008 NHLBI/NIH guidelines. Am J Hematol 2009; 84: 366-70.
5. Howard MA, Firkin BG. Ristocetin: a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971; 26: 326-9.
6. Favaloro EJ, Bonar R, Chapman K, Meiring M, Funk D. Differential sensitivity of von Willebrand factor activity assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofator, collagen-binding and mAb assays. J Thromb Haemost 2012; 10: 1043-54.
7. Batlle J, Perez-Rodriguez A, Franqueira MD, Lopez-Fernandez MF. Type 2M von Willebrand disease: a variant of Type 2A? J Thromb Haemost 2008; 6: 388-90.
8. Batlle J, Lopez Fernandez MF, Campos M, Justica B, Berges C, Navarro JL et al. The heterogenecity of Type IIA von Willebrand′s disease: studies with protease inhibitors. Blood 1986; 68: 1207-12.
9. Batlle J, López Fernández MF, López Berges C, López Borrasca A. Electroblotting of Factor VIII/von Willebrand Factor multimers after electrophoresis in SDS-agarose gel, discontinuous buffer system. Br J Haematol 1983; 55: 195-6.
10. Fernández MF, Ginsberg MH, Ruggeri ZM, Batlle FJ, Zimmerman TS. Multimeric structure of platelet Factor VIII/von Willebrand Factor: The presence of larger multimers and their reassociation with thrombin stimulated platelets. Blood 1982; 60: 1132-8.
11. Mannucci PM. Genetic testing in von Willebrand disease: a rebuttal. J Thromb Haemost 2010; 8: 860; author reply 861.
12. Favaloro EJ, Bonar R, Marsden K. Lower limit of assay sensitivity: an under-recognized and significant problem in von Willebrand disease identification and classification. Clin Lab Sci 2008; 21: 178-83.
13. Kitchen S, Jennings I, Woods TA, Kitchen DP, Walker ID, Preston FE. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom national external quality assessment scheme for blood coagulation. Semin Thromb Hemost 2006; 32: 492-8.
14. Miller CH, Platt SJ, Daniele C, Kaczor D. Evaluation of two automated methods for measurement of the ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2002; 88: 56-9.
15. Lawrie AS, Makie IJ, Machin SJ, Peyvandi F. Evaluation of an automated platelet-based assay of ristocetin cofactor activity. Haemophilia 2011; 17: 252-6.
16. Favaloro EJ, Mohamed S, McDonald J. Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay. J Thromb Haemost 2010; 8: 2842-4.
17. Hillarp A, Stadler M, Haderer C, Weinberger J, Kessler CM, Romisch J. Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay using a novel automated assay protocol. J Thromb Haemost 2010; 8: 2216-23.
18. Chen D, Daigh CA, Hendricksen JI et al. A highly-sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry. J Thromb Haemost 2008; 6: 323-30.
19. De Vleeschauwer A, Devreese K. Comparison of a new automated von Willebrand factor activity assay with an aggregation von Willebrand ristocetin cofactor activity assay for the diagnosis of von Willebrand disease. Blood Coagul Fibrinolysis 2006; 17: 353-8.
20. Favaloro EJ, Henniker A, Facey D, Hertzberg M. Discrimination of von Willebrand disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems. Thromb Haemost 2000; 84: 541-7.
21. Sucker C, Senft B, Scharf RE, Zots RB. Determination of von Willebrand factor activity: evaluationof the HaemosIL assay in comparison with established procedures. Clin Appl Thromb Hemost 2006; 12: 305-10.
22. Vanhoorelbeke K, Cauwenberghs N, Vauterin S, Schlammadinger A, Mazurier C, Deckmyn H. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2000; 83: 107-13.
23. Bodó I. Assay systems to measure platelet-dependent von Willebrand factor activity (GPIbα binding). ECAT Found 2012; Special Issue 2: 27-32.
24. Murdock PJ, Woodhams BJ, Matthews KB, Pasi KJ, Goodall AH. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost 1997; 78: 1272-7.
25. Flood VH, Gill JC, Morateck PA et al. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood 2011; 117: e67-74.
26. Lawrie AS, Stufano F, Canciani MT, Mackie IJ, Machin SJ, Peyvandi F. A comparative evaluation of a new automated assay for von Willebrand factor activity. Hemophilia 2013; 19: 338-42.
27. Verfaillie CJ, De Witte E., Devreese KMJ. Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease. Int J Lab Hematol 2013; 35: 555-65.
28. Cabrera N, Moret A, Caunedo P, Cid AR, Vila V, España F et al. Comparison of a new chemiluninescent immunoassay for von Wilebrand factor activity with the ristocetin cofactor-induce platelet agglutination method. Haemophilia 2013; 19: 920-5.
29. Stufano F, Lawrie AS, La Marca S, Berbenni C, Baronciani L, Peyvandi F. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen. Haemophilia 2014; 20: 147-53.
30. Budde U, Schneppenheim R, Plendl H, Dent J, Ruggeri ZM, Zimmerman TS. Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes. Thromb Haemost 1990; 63: 312-5.
31. Noya MS, Batlle J. Tratamiento de la Enfermedad de von Willebrand. In: Batlle Fonrodona J, Rocha Hernando E Eds. Guía Práctica de Coagulopatías Congénitas. Madrid, Acción Médica S.A., 2001: 181-204.
32. Rendal E, Penas N, Larrabeiti B et al. Type 2B von Willebrand's disease due to Val1316Met mutation. Heterogeneity in the same sibship. Ann Hematol 2001; 80: 354-60.
33. Rongen HA, Hoetelmans RM, Bult A, van Bennekom WP. Chemiluminescence and immunoassays. J Pharm Biomed Anal 1994; 12: 433-62.
34. Cheng LW, Stanker LH. Detection of Botulinum Neurotoxin Serotypes A and B Using a Chemiluminescent versus Electrochemiluminescent Immunoassay in Food and Serum. J Agric Food Chem 2013; 61: 755-60.
35. De Moerloose P, Reber G, Musial J, Arnout J. Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome. J Thromb Haemost 2010; 8: 1540-6.
36. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, et al. Phenotype and genotype of a cohort of families historically diagnosed with Type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 1(109): 112-21.
37. Batlle J, Pérez Rodríguez A, López Fernández MF. Classification of von Willebrand disease. In: Federici A, Lee C, Berntorp E, Lillicrap D, Montgomery B Eds. Von Willebrand Disease: Basic and Clinical Aspects. London, Wiley-Blackwell, 2011: 74-85.
38. Federici AB, Canciani MT. Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease. Haematologica 2009; 94(5): 610-5.
39. Castaman G, Goodeve A, Eikenboom J. European Group on von Willebrand Disease. Principles of care for the diagnosis abd treatment of von Willebrand Disease. Haematologica 2013; 95(5): 667-374. doi:10.3324/haematol.2012.077263